Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michel Allé | M | 74 |
Université Libre de Bruxelles
| 27 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Kiss | M | - |
Unibioscreen SA
 Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline.
Université Libre de Bruxelles
| 15 years |
| Yvan de Launoit | M | - |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | 12 years |
| Tanguy Cornet | M | - |
Université Libre de Bruxelles
| 5 years |
| Jean-Luc Samuel Francois Girardet | M | 57 |
Université de Montpellier
| 8 years |
| Piotr Tyranowski | M | - |
Université Libre de Bruxelles
| 4 years |
| Ugo Falcinelli | M | - |
Université Libre de Bruxelles
| 4 years |
| Alexey Viktorovich Lapikov | M | 48 |
Université de Montpellier
| 4 years |
| Tuan Van Nguyen | M | 54 |
Université Libre de Bruxelles
| 2 years |
| Stéphanie Vanden Broecke | F | - |
Université Libre de Bruxelles
| 3 years |
| Herjan Coelingh Bennink | M | - |
Université Libre de Bruxelles
| 8 years |
| Aminata Kaké | F | 47 |
Université Libre de Bruxelles
| 4 years |
| Nourredine Chinek | M | - |
Université Libre de Bruxelles
| 4 years |
| Frederic Halkin | M | - |
Université Libre de Bruxelles
| 1 years |
| Emmanuel Lacroix | M | - |
Université Libre de Bruxelles
| 4 years |
| Muriel de Lathouwer | F | 51 |
Université Libre de Bruxelles
| 4 years |
| Huong Giang Thi Luong | F | 57 |
Université Libre de Bruxelles
| 2 years |
| Benoît Taymans | M | - |
Université Libre de Bruxelles
| 4 years |
| Daniel Grossmann | M | 53 |
Université Libre de Bruxelles
| 5 years |
| Ayuporn Karnasuta | F | - |
Université Libre de Bruxelles
| 2 years |
| Alice Guilhon Lanfranchi | M | 57 |
Université de Montpellier
| 3 years |
| Gonzalo Tradacete Gallart | M | - |
Université Libre de Bruxelles
| 5 years |
| Ann J. Barbier | M | 59 |
Université Libre de Bruxelles
| 3 years |
| Bernd Karl-Friedrich Starrock | M | - |
Université de Montpellier
| 2 years |
| Bo I. Nilsson | M | - |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
| Steven D. Weitman | M | - |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
| Marc Hellemans | M | 51 |
Université Libre de Bruxelles
| 4 years |
| Alain Parthoens | M | 64 |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
| Kristel Verleyen | F | 53 |
Université Libre de Bruxelles
| 3 years |
| Amelie Coens | F | - |
Université Libre de Bruxelles
| 4 years |
| Dimitri Dimitriou | M | - |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
| Matthias de Raeymaeker | M | 49 |
Université Libre de Bruxelles
| 2 years |
| Antoine Duchateau | M | 70 |
Université Libre de Bruxelles
| 1 years |
| Keith Bragman | M | - |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
| Frédéric Zoller | M | - |
Université Libre de Bruxelles
| 4 years |
| Christiane Verhaegen | F | - |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | 5 years |
| Didier Georges | M | - |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
| Sven Arne Andréasson | M | 72 |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
| Sandrine Evrard | F | - |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
| Mathieu Francois Pierre Pasture | M | - |
Université Libre de Bruxelles
| 1 years |
| Sandrine Gautier | M | - |
Université de Montpellier
| 3 years |
| Abderrezak Kamel | M | - |
Université de Montpellier
| 1 years |
| Etienne van de Kerckhove | M | 60 |
Université Libre de Bruxelles
| 1 years |
| Frank van Vynckt | M | - |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
| Eric van Quaquebeke | M | - |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | 9 years |
| Marie Wintrebert-Fouquet | M | - |
Université de Montpellier
| 3 years |
| Didier Malherbe | M | - |
Unibioscreen SA
Unibioscreen SA Pharmaceuticals: MajorHealth Technology Unibioscreen is a privately held specialist oncology discovery & development company. Founded in 1999 and based in Brussels, Belgium. Unibioscreen has successfully discovered, patented and developed 2 novel, first-in-class anti-cancer drug candidates (chemotherapeutics) now in clinical phase I in cancer patients and has also a discovery pipeline. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Belgium | 40 | 85.11% |
| France | 7 | 14.89% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Francis Darro
- Personal Network
